Coherus Biosciences | CHRS - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 1000K 2026-06
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Akebia Therapeutics USD 63.08M 8.26M 2025-12
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amarin USD 51.48M 113K 2025-12
Amgen USD 11.69B 6.9B 2026-06
Baxter International USD 2.68B 3.36B 2026-06
Biogen USD 2.98B 1.02B 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.52B 496M 2026-06
Fujifilm JPY 825.49B 58.1B 2026-03
Gilead Sciences USD 3.95B 19.57B 2026-06
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Merck USD 15.77B 2.4B 2026-06
Myriad Genetics USD 212.8M 16.2M 2025-12
Pacira USD 180.54M 7.79M 2026-06
Perrigo USD 290.5M 645.1M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD 226.66M 19.64M 2026-03
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Teva Pharmaceutical Industries USD 3.92B 691M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06
Xencor USD 87.82M 5.44M 2026-06
Zoetis USD 3.15B 85M 2026-06